Production (Stage)
Century Therapeutics, Inc.
IPSC
$0.583
$0.00761.32%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 8,286.79% | 194.85% | 7.92% | -55.26% | -76.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8,286.79% | 194.85% | 7.92% | -55.26% | -76.63% |
| Cost of Revenue | 21.01% | 15.68% | 4.34% | 30.75% | 21.68% |
| Gross Profit | 105.00% | -11.25% | -4.24% | -36.47% | -30.01% |
| SG&A Expenses | -1.07% | -0.56% | -1.07% | 3.55% | 3.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.95% | 11.25% | 2.91% | -1.66% | -6.37% |
| Operating Income | 76.14% | -7.98% | -2.82% | -0.25% | 3.17% |
| Income Before Tax | 84.82% | 7.43% | -3.62% | -5.51% | -7.62% |
| Income Tax Expenses | 165.58% | -4.78% | -130.70% | -111.47% | -47.47% |
| Earnings from Continuing Operations | 83.56% | 7.39% | -0.73% | -3.47% | -7.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 83.56% | 7.39% | -0.73% | -3.47% | -7.05% |
| EBIT | 76.14% | -7.98% | -2.82% | -0.25% | 3.17% |
| EBITDA | 85.25% | -8.67% | -2.07% | 1.30% | 6.12% |
| EPS Basic | 87.34% | 29.57% | 15.22% | 6.06% | -3.50% |
| Normalized Basic EPS | 87.82% | 18.13% | 17.59% | 14.79% | 12.84% |
| EPS Diluted | 87.34% | 29.57% | 15.22% | 6.06% | -3.50% |
| Normalized Diluted EPS | 87.78% | 18.13% | 17.59% | 14.79% | 12.84% |
| Average Basic Shares Outstanding | 40.35% | 32.53% | 22.70% | 12.68% | 3.62% |
| Average Diluted Shares Outstanding | 40.38% | 32.53% | 22.70% | 12.68% | 3.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |